Search for a trial

Cognitive Decline in Older Patients with End stage Renal Disease

Knowledge on the magnitude of the decline and the pathophysiological mechanism can eventually help us topostulate an algorithm for well-balanced decision making in treatment strategies in the elderly CKD patients.This knowledge will be firmly…

Behavioral and psychological characteristics of children with narcolepsy

With this study we aim to investigate the emotional development, behavior, social behavior, variation in personality traits and intellectual functioning in a group of children who are diagnosed with narcolepsy with of without cataplexie, according…

Assessment of blood flow velocity and oximetry using non-invasive retinal and cutaneous microcirculation imaging in sickle cell disease (SCD) patients and healthy volunteers.

Assessment of the cutaneous and retinal microcirculation in SCD patients and matched controls:- Long- and short-term repeatability of LSCI and NiRFI ;- Comparison of cutaneous and retinal microcirculation between SCD patients and matched healthy…

The value of nerve ultrasound in patients with neurofibromatosis type 1

This will be an explorative study to examine the value of high-resolution ultrasound (HRUS) of the peripheral nerves in NF1 patients. The primary objective of this study is to determine HRUS abnormalities in a large group of NF1 patients, and to…

A phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding trial to evaluate the efficacy and safety of IMU-838 for treatment of patients with active Crohn*s disease with an option for open-label treatment extension (CALDOSE-2)

Primary objective• To determine the optimal dose of IMU-838 to induce symptomatic remission (based on stool frequency [SF] and abdominal pain [AP], as assessed in the Crohn*s Disease Activity Index [CDAI] patient reported outcome [PRO]-2) in…

Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies (study 208750)

This study has been transitioned to CTIS with ID 2024-513033-21-00 check the CTIS register for the current data. Primary:• To monitor participants for delayed AEs associated with administration of autologous cells that have been genetically modified…

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

This study has been transitioned to CTIS with ID 2022-500785-10-00 check the CTIS register for the current data. 1) To compare pembrolizumab plus enzalutamide versus placebo plus enzalutamide with respect to overall survival (OS)2) To compare…

A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CA209-76K)

This study has been transitioned to CTIS with ID 2022-502354-14-00 check the CTIS register for the current data. Primary Objective:To measure the efficacy provided by nivolumab therapy on its own compared to placebo in participants who have had…

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis. SELECT-GCA

This study has been transitioned to CTIS with ID 2023-505476-29-00 check the CTIS register for the current data. This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week…

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO) (study 208467)

This study has been transitioned to CTIS with ID 2024-513032-14-00 check the CTIS register for the current data. Primary:To evaluate the efficacy of NY-ESO-1-Specific (c259) T Cells, alone or in combination with other anti-cancer agents, in HLA-A*02…

A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma (KEYNOTE 966)

This study has been transitioned to CTIS with ID 2023-506657-38-00 check the CTIS register for the current data. To compare pembrolizumab plus gemcitabine plus cisplatin to placebo plus gemcitabine plus cisplatin with respect to overall survival (OS…

Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy

This study has been transitioned to CTIS with ID 2024-511252-41-00 check the CTIS register for the current data. The aim of the current study is to extend the time to develop new disease progression in prostate cancer patients with recurrent disease…

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of Rilzabrutinib (PRN1008), an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenia

This study has been transitioned to CTIS with ID 2023-509397-39-00 check the CTIS register for the current data. Part A: Safety:• To characterize the safety and tolerability of up to four dose levels of rilzabrutinibin patients with ITPEfficacy:• To…

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

This study has been transitioned to CTIS with ID 2023-508365-33-00 check the CTIS register for the current data. To determine the efficacy of ALNTTRSC02 in patients with hATTR amyloidosis by evaluating the effect on neurologic impairment. To…

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma

This study has been transitioned to CTIS with ID 2023-506587-13-00 check the CTIS register for the current data. The safety and efficacy of JNJ-68284528 in heavily pretreated patients with multiple myeloma is being evaluated in the Phase 1b/2 Study…

A Phase III, multicenter, randomized, double-blind study to assess efficacy and safety of two doses of crizanlizumab versus placebo, with or without hydroxyureal/hydroxycarbamide therapy, in adolescent and adult sickle cell disease patients with vaso-occlusive crises (STAND)

This study has been transitioned to CTIS with ID 2023-508689-14-00 check the CTIS register for the current data. To compare the efficacy of 7.5 mg/kg of crizanlizumab versus placebo on the annualized rate of VOC leading to healthcare visit, in…

The roles of Attachment Style and Autonomy on Inter-Personal Distance and respons time in Virtual Reality in patients with persistent psychopathology.

Examining inter-personal distance in Virtual Reality in patients with persisting psychopathology and a control group in order to assess the association with attachment styles. Differences in gender will also be examined. Primary research question…

Triathlon Tritanium Tibia Registery; national multicentre surveillance register

To verify the uncemented Triathlon Tritanium Knee System safety during follow-up and survivorship as described by Kaplan-Meier survival curves.To document the patient clinical outcome of the patients who have received an uncemented knee arthroplasty…

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator*s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

This study has been transitioned to CTIS with ID 2023-509349-11-00 check the CTIS register for the current data. Primary objective: To determine the efficacy of the combination of acalabrutinib and venetoclax without obinutuzumab (AV; Arm A), or…

The uptake of radioactive iodine before and after a low iodine diet in patients with differentiated thyroid carcinoma

Primary objective: 1. To compare the difference in thyroid uptake of a low tracer dose radioactive iodine (10 MBq 123I or 37 MBq 123I) (1a), in DTC patients after thyroidectomy, before and after a LID of 7 days (1b).Primary objective described in…